https://www.selleckchem.com/products/vt103.html
Treatment of proliferative GN with monoclonal Ig deposits (PGNMID) is not established. A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma. Abnormal plasma cell clones may play a role in the pathogenesis of PGNMID. We evaluated daratumumab's safety and efficacy in an open-label, phase 2 trial in 11 adults with PGNMID and one with C3 glomerulopathy (C3G) with monoclonal gammopathy. Patients had an eGFR 20 ml/min per 1.73 m and proteinuria 1 g/d. They received daratumumab intravenously (16 mg/kg)
Gefällt mir
Kommentar
Teilen
